Ambulanzen
Schilddrüsenambulanz der Klinik für Nuklearmedizin
In unserer Schilddrüsenambulanz bieten wir unseren Patientinnen und Patienten eine umfassende Diagnostik und Therapie von Schilddrüsenerkrankungen. Unsere Klinik ist mit einem modernen Ultraschallgerät und einer modernen Schilddrüsenkamera sowie zwei SPECT/CTs ausgestattet. Auf unserer Therapiestation bieten wir die Radiojodtherapie sowohl bei gutartigen Schilddrüsenerkrankungen wie z.B. bei einer Autonomie oder Basedow als auch bei einem Schilddrüsenkarzinom an.
Der Therapiegarten unserer Therapiestation ermöglicht unseren Patientinnen und Patienten einen schönen Aufenthalt. Wir arbeiten eng mit der hiesigen Abteilung für Allgemein- und Viszeralchirurgie zusammen und arrangieren, falls eine Schilddrüsenoperation notwendig wird, für Sie ein Beratungsgespräch mit unseren Schilddrüsenoperateuren.
Darüber hinaus bieten wir auch Beratungsgespräche zur Einholung einer Zweitmeinung an. Hierfür bitten wir Sie, Ihre Vorbefunde, Laborwerte und Ihre Medikamentenliste mitzubringen.
Der Therapiegarten unserer Therapiestation ermöglicht unseren Patientinnen und Patienten einen schönen Aufenthalt. Wir arbeiten eng mit der hiesigen Abteilung für Allgemein- und Viszeralchirurgie zusammen und arrangieren, falls eine Schilddrüsenoperation notwendig wird, für Sie ein Beratungsgespräch mit unseren Schilddrüsenoperateuren.
Darüber hinaus bieten wir auch Beratungsgespräche zur Einholung einer Zweitmeinung an. Hierfür bitten wir Sie, Ihre Vorbefunde, Laborwerte und Ihre Medikamentenliste mitzubringen.
Nuklear-Onkologische Ambulanz
Unsere Nuklear-Onkologische Ambulanz bietet Patientinnen und Patienten mit neuroendokrinen Tumoren sowie metastasiertem Prostatakarzinom umfassende Beratungsgespräche zum Thema Radionuklidtherapie (Radiopeptidtherapie (PRRT) sowie PSMA-Therapie und Therapie mit Ra-223). Therapieplanungen sowie Therapieerfolgskontrollen erfolgen ebenfalls in dieser Ambulanz.
Die Therapiestation wurde komplett umgebaut, modernisiert und entspricht allen Erwartungen an eine moderne nuklearmedizinische Station. Auf der Therapiestation haben wir neben zwei Einzelbettzimmern und zwei Doppelbettzimmern (insgesamt 6 Betten) auch einen Therapiegarten mit einem großen überdachten Bereich, in dem es sogar bei schlechtem Wetter möglich ist, draußen eine Tasse Kaffee zu trinken und frische Luft zu schnappen.
Herr Prof. Dr. med. Hojjat Ahmadzadehfar (Chefarzt der Klinik) und Frau PD Dr. med. Anna Yordanova (Ltd Oberärztin) beschäftigen sich beide seit Jahren mit der Diagnostik und Behandlung solcher Tumore mittels Radionukliden. Unten finden Sie eine Liste gewählter Publikationen dieser beiden ärztlichen Fachkräfte.
Die Therapiestation wurde komplett umgebaut, modernisiert und entspricht allen Erwartungen an eine moderne nuklearmedizinische Station. Auf der Therapiestation haben wir neben zwei Einzelbettzimmern und zwei Doppelbettzimmern (insgesamt 6 Betten) auch einen Therapiegarten mit einem großen überdachten Bereich, in dem es sogar bei schlechtem Wetter möglich ist, draußen eine Tasse Kaffee zu trinken und frische Luft zu schnappen.
Herr Prof. Dr. med. Hojjat Ahmadzadehfar (Chefarzt der Klinik) und Frau PD Dr. med. Anna Yordanova (Ltd Oberärztin) beschäftigen sich beide seit Jahren mit der Diagnostik und Behandlung solcher Tumore mittels Radionukliden. Unten finden Sie eine Liste gewählter Publikationen dieser beiden ärztlichen Fachkräfte.
1. Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC.
Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, Delpassand ES, Abbaspour F, Salehi Y, Biersack HJ, Ahmadzadehfar H.
Cancers (Basel). 2022 Apr 10;14(8):1914. doi: 10.3390/cancers14081914.
PMID: 35454822 Free PMC article. Review.
2. Radioembolization, Principles and indications.
Ahmadzadehfar H, Ilhan H, Lam MGEH, Sraieb M, Stegger L.
Nuklearmedizin. 2022 Mar 30. doi: 10.1055/a-1759-4238. Online ahead of print.
PMID: 35354218 English.
3. Combination Therapies with PRRT.
Yordanova A, Ahmadzadehfar H.
Pharmaceuticals (Basel). 2021 Sep 30;14(10):1005. doi: 10.3390/ph14101005.
PMID: 34681229 Free PMC article. Review.
4. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.
Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, Kamali H, Ebrahimi S, Shakibazad N, Jokar N, Nabipour I, Ahmadzadehfar H.
Clin Nucl Med. 2021 Nov 1;46(11):e523-e530. doi: 10.1097/RLU.0000000000003810.
PMID: 34269729
5. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bögemann M, Kratochwil C, Rathke H, Ilhan H, Svirydenka H, Sathekge M, Kabasakal L, Yordanova A, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I, Rahbar K.
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4067-4076. doi: 10.1007/s00259-021-05383-3. Epub 2021 May 25.
PMID: 34031719
6. Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.
Yordanova A, Biersack HJ, Ahmadzadehfar H.
J Clin Med. 2020 Nov 16;9(11):3679. doi: 10.3390/jcm9113679.
PMID: 33207788 Free PMC article. Review.
7. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Sraieb M, Hirmas N, Conrad R, Marinova M, Essler M, Herrmann K, Ahmadzadehfar H.
Medicine (Baltimore). 2020 Sep 18;99(38):e22287. doi: 10.1097/MD.0000000000022287.
PMID: 32957385 Free PMC article.
8. Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Marinova M, Alamdar R, Ahmadzadehfar H, Essler M, Attenberger U, Mücke M, Conrad R.
Nuklearmedizin. 2020 Dec;59(6):409-414. doi: 10.1055/a-1234-5891. Epub 2020 Aug 21.
PMID: 32823294 Clinical Trial. English.
9. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, Kulkarni HR, Zhang J, Gerke C, Fimmers R, Kratochwil C, Rathke H, Ilhan H, Maffey-Steffan J, Sathekge M, Kabasakal L, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I.
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122. doi: 10.1007/s00259-020-04797-9. Epub 2020 May 8.
PMID: 32383093 Free PMC article.
10. PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.
Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ.
Semin Nucl Med. 2020 Jan;50(1):98-109. doi: 10.1053/j.semnuclmed.2019.07.003. Epub 2019 Aug 21.
PMID: 31843065 Review.
11. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy.
Assadi M, Nemati R, Shooli H, Rekabpour SJ, Nabipour I, Jafari E, Gholamrezanezhad A, Amini A, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):1015-1016. doi: 10.1007/s00259-019-04578-z. Epub 2019 Nov 18.
PMID: 31741022 No abstract available.
12. The value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapy.
Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R, Essler M, Holdenrieder S, Ahmadzadehfar H.
Prostate. 2020 Jan;80(1):17-27. doi: 10.1002/pros.23912. Epub 2019 Oct 3.
PMID: 31579967
13. Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study.
Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, Tavakoli M, Pirayesh E, Ahmadzadehfar H.
World J Nucl Med. 2019 Jul-Sep;18(3):258-265. doi: 10.4103/wjnm.WJNM_66_18.
PMID: 31516369 Free PMC article.
14. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy.
Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2252-2259. doi: 10.1007/s00259-019-04431-3. Epub 2019 Jul 24.
PMID: 31338547
15. Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.
Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, Lam M, de Keizer B, Fischer HP, Kristiansen G.
Oncotarget. 2019 Jun 25;10(41):4149-4160. doi: 10.18632/oncotarget.27024. eCollection 2019 Jun 25.
PMID: 31289613 Free PMC article.
16. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M.
Clin Nucl Med. 2019 May;44(5):e329-e335. doi: 10.1097/RLU.0000000000002532.
PMID: 30932975
17. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Ahmadzadehfar H, Essler M.
Eur Urol. 2020 Apr;77(4):418-419. doi: 10.1016/j.eururo.2019.02.028. Epub 2019 Mar 2.
PMID: 30833140 No abstract available.
18. Radionuclide intake risks in the clinical administration of 223RaCl2.
Scholl C, Bundschuh RA, Hirzebruch S, Glanert T, Wei X, Kürpig S, Rödel R, Essler M, Thomas L, Ahmadzadehfar H.
J Radiol Prot. 2019 Jun;39(2):387-398. doi: 10.1088/1361-6498/ab044d. Epub 2019 Feb 4.
PMID: 30716726
19. 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, von Mallek D, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1054-1062. doi: 10.1007/s00259-019-4258-6. Epub 2019 Jan 29.
PMID: 30697649
20. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H.
Endocr Relat Cancer. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424.
PMID: 30540557
21. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.
Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, Gaertner FC, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24.
PMID: 30474706
22. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A.
PET Clin. 2018 Oct;13(4):491-503. doi: 10.1016/j.cpet.2018.05.005. Epub 2018 Aug 17.
PMID: 30219184 Review.
23. [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.
Rahbar K, Ahmadzadehfar H, Seifert R, Boegemann M.
Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8.
PMID: 30102221 No abstract available.
24. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Fimmers R, Essler M, Ahmadzadehfar H.
Clin Cancer Res. 2018 Oct 1;24(19):4672-4679. doi: 10.1158/1078-0432.CCR-18-0947. Epub 2018 Jun 27.
PMID: 29950352
25. PSMA Theranostics: Current Status and Future Directions.
Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H.
Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068.
PMID: 29873291 Free PMC article. Review.
26. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
Awang ZH, Essler M, Ahmadzadehfar H.
Radiat Oncol. 2018 May 23;13(1):98. doi: 10.1186/s13014-018-1037-7.
PMID: 29792198 Free PMC article. Review.
27. BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
Ahmadzadehfar H, Gaertner F, Lossin PS, Schwarz B, Essler M.
Clin Nucl Med. 2018 Aug;43(8):609-610. doi: 10.1097/RLU.0000000000002141.
PMID: 29762244
28. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M.
Urologe A. 2018 Jun;57(6):709-713. doi: 10.1007/s00120-018-0642-2.
PMID: 29671080 German.
29. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy.
Ahmadzadehfar H, Essler M.
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
PMID: 29653975 No abstract available.
30. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G.
Breast Cancer Res Treat. 2018 Jun;169(3):447-455. doi: 10.1007/s10549-018-4717-y. Epub 2018 Feb 17.
PMID: 29455299
31. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.
Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M.
Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28.
PMID: 29262549 Free PMC article.
32. 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
Rahbar K, Ahmadzadehfar H, Boegemann M.
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):513-514. doi: 10.1007/s00259-017-3892-0. Epub 2017 Nov 21.
PMID: 29164300 No abstract available.
33. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246. doi: 10.1007/s00259-017-3877-z. Epub 2017 Nov 13.
PMID: 29134280
34. Theranostics in nuclear medicine practice.
Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, Essler M.
Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671. eCollection 2017.
PMID: 29042793 Free PMC article. Review.
35. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19. doi: 10.1007/s00259-017-3848-4. Epub 2017 Oct 12.
PMID: 29026946
36. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.
Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M.
Oncotarget. 2017 Jul 6;8(33):55094-55103. doi: 10.18632/oncotarget.19049. eCollection 2017 Aug 15.
PMID: 28903405 Free PMC article.
37. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.
Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M.
Oncotarget. 2017 Feb 25;8(33):55567-55574. doi: 10.18632/oncotarget.15698. eCollection 2017 Aug 15.
PMID: 28903443 Free PMC article.
38. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46. doi: 10.1007/s00259-017-3816-z. Epub 2017 Sep 1.
PMID: 28864881
39. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763.
PMID: 28719450
40. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. doi: 10.1007/s00259-017-3716-2. Epub 2017 May 9.
PMID: 28488028
41. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479. doi: 10.1007/s00259-017-3681-9. Epub 2017 Mar 23.
PMID: 28337529
42. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.
Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214. doi: 10.1007/s00259-017-3652-1. Epub 2017 Mar 1.
PMID: 28246882
43. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.
Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M.
Horm Metab Res. 2017 Feb;49(2):77-85. doi: 10.1055/s-0042-121894. Epub 2017 Jan 18.
PMID: 28099977 Review.
44. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ.
J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.
PMID: 27765862
45. Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis.
Yordanova A, Mayer K, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Dec;41(12):977-979. doi: 10.1097/RLU.0000000000001386.
PMID: 27749410
46. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Wei X, Schlenkhoff C, Sopora C, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Nov;41(11):894-895. doi: 10.1097/RLU.0000000000001358.
PMID: 27607162
47. 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.
Rahbar K, Bögemann M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):166-167. doi: 10.1007/s00259-016-3530-2. Epub 2016 Oct 4.
PMID: 27699719 No abstract available.
48. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.
Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, Kürpig S, Strunk H, Essler M.
J Nucl Med. 2017 Mar;58(3):438-444. doi: 10.2967/jnumed.116.178533. Epub 2016 Sep 22.
PMID: 27660148
49. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H.
J Nucl Med. 2017 Feb;58(2):312-319. doi: 10.2967/jnumed.116.178228. Epub 2016 Sep 1.
PMID: 27587707
50. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H.
J Nucl Med. 2016 Sep;57(9):1334-8. doi: 10.2967/jnumed.116.173757. Epub 2016 Apr 7.
PMID: 27056618
51. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Schlenkhoff CD, Knüpfer E, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Jul;41(7):572-3. doi: 10.1097/RLU.0000000000001200.
PMID: 26909718
52. Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Jun;41(6):478-80. doi: 10.1097/RLU.0000000000001195.
PMID: 26909716
53. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M.
Oncotarget. 2016 Mar 15;7(11):12477-88. doi: 10.18632/oncotarget.7245.
PMID: 26871285 Free PMC article.
54. 68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.
Schlenkhoff CD, Gaertner F, Essler M, Hauser S, Ahmadzadehfar H.
Clin Nucl Med. 2016 May;41(5):423-5. doi: 10.1097/RLU.0000000000001158.
PMID: 26859213
55. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M, Essler M.
EJNMMI Res. 2015 Dec;5(1):114. doi: 10.1186/s13550-015-0114-2. Epub 2015 Jun 20.
PMID: 26099227 Free PMC article.
56. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, Biersack HJ, Guhlke S, Reichmann K.
Clin Nucl Med. 2012 Jun;37(6):e141-7. doi: 10.1097/RLU.0b013e31823926e5.
PMID: 22614212
57. Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy.
Sabet A, Ezziddin S, Heinemann F, Guhlke S, Muckle M, Willinek W, Biersack HJ, Ahmadzadehfar H.
Nuklearmedizin. 2012;51(3):95-100. doi: 10.3413/Nukmed-0428-11-08. Epub 2012 Mar 16.
PMID: 22421930
58. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.
Ezziddin S, Lauschke H, Schaefers M, Meyer C, van Essen M, Biersack HJ, Kwekkeboom DJ, Ahmadzadehfar H.
Clin Nucl Med. 2012 Jan;37(1):102-4. doi: 10.1097/RLU.0b013e318238f111.
PMID: 22157044 No abstract available.
59. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy.
Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, Brockmann H, Willinek W, Wardelmann E, Biersack HJ, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):459-66. doi: 10.1007/s00259-010-1610-2. Epub 2010 Sep 18.
PMID: 20852858
Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, Delpassand ES, Abbaspour F, Salehi Y, Biersack HJ, Ahmadzadehfar H.
Cancers (Basel). 2022 Apr 10;14(8):1914. doi: 10.3390/cancers14081914.
PMID: 35454822 Free PMC article. Review.
2. Radioembolization, Principles and indications.
Ahmadzadehfar H, Ilhan H, Lam MGEH, Sraieb M, Stegger L.
Nuklearmedizin. 2022 Mar 30. doi: 10.1055/a-1759-4238. Online ahead of print.
PMID: 35354218 English.
3. Combination Therapies with PRRT.
Yordanova A, Ahmadzadehfar H.
Pharmaceuticals (Basel). 2021 Sep 30;14(10):1005. doi: 10.3390/ph14101005.
PMID: 34681229 Free PMC article. Review.
4. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.
Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, Kamali H, Ebrahimi S, Shakibazad N, Jokar N, Nabipour I, Ahmadzadehfar H.
Clin Nucl Med. 2021 Nov 1;46(11):e523-e530. doi: 10.1097/RLU.0000000000003810.
PMID: 34269729
5. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bögemann M, Kratochwil C, Rathke H, Ilhan H, Svirydenka H, Sathekge M, Kabasakal L, Yordanova A, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I, Rahbar K.
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4067-4076. doi: 10.1007/s00259-021-05383-3. Epub 2021 May 25.
PMID: 34031719
6. Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.
Yordanova A, Biersack HJ, Ahmadzadehfar H.
J Clin Med. 2020 Nov 16;9(11):3679. doi: 10.3390/jcm9113679.
PMID: 33207788 Free PMC article. Review.
7. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Sraieb M, Hirmas N, Conrad R, Marinova M, Essler M, Herrmann K, Ahmadzadehfar H.
Medicine (Baltimore). 2020 Sep 18;99(38):e22287. doi: 10.1097/MD.0000000000022287.
PMID: 32957385 Free PMC article.
8. Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Marinova M, Alamdar R, Ahmadzadehfar H, Essler M, Attenberger U, Mücke M, Conrad R.
Nuklearmedizin. 2020 Dec;59(6):409-414. doi: 10.1055/a-1234-5891. Epub 2020 Aug 21.
PMID: 32823294 Clinical Trial. English.
9. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, Kulkarni HR, Zhang J, Gerke C, Fimmers R, Kratochwil C, Rathke H, Ilhan H, Maffey-Steffan J, Sathekge M, Kabasakal L, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I.
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122. doi: 10.1007/s00259-020-04797-9. Epub 2020 May 8.
PMID: 32383093 Free PMC article.
10. PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.
Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ.
Semin Nucl Med. 2020 Jan;50(1):98-109. doi: 10.1053/j.semnuclmed.2019.07.003. Epub 2019 Aug 21.
PMID: 31843065 Review.
11. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy.
Assadi M, Nemati R, Shooli H, Rekabpour SJ, Nabipour I, Jafari E, Gholamrezanezhad A, Amini A, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):1015-1016. doi: 10.1007/s00259-019-04578-z. Epub 2019 Nov 18.
PMID: 31741022 No abstract available.
12. The value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapy.
Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R, Essler M, Holdenrieder S, Ahmadzadehfar H.
Prostate. 2020 Jan;80(1):17-27. doi: 10.1002/pros.23912. Epub 2019 Oct 3.
PMID: 31579967
13. Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study.
Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, Tavakoli M, Pirayesh E, Ahmadzadehfar H.
World J Nucl Med. 2019 Jul-Sep;18(3):258-265. doi: 10.4103/wjnm.WJNM_66_18.
PMID: 31516369 Free PMC article.
14. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy.
Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2252-2259. doi: 10.1007/s00259-019-04431-3. Epub 2019 Jul 24.
PMID: 31338547
15. Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging.
Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, Lam M, de Keizer B, Fischer HP, Kristiansen G.
Oncotarget. 2019 Jun 25;10(41):4149-4160. doi: 10.18632/oncotarget.27024. eCollection 2019 Jun 25.
PMID: 31289613 Free PMC article.
16. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M.
Clin Nucl Med. 2019 May;44(5):e329-e335. doi: 10.1097/RLU.0000000000002532.
PMID: 30932975
17. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Ahmadzadehfar H, Essler M.
Eur Urol. 2020 Apr;77(4):418-419. doi: 10.1016/j.eururo.2019.02.028. Epub 2019 Mar 2.
PMID: 30833140 No abstract available.
18. Radionuclide intake risks in the clinical administration of 223RaCl2.
Scholl C, Bundschuh RA, Hirzebruch S, Glanert T, Wei X, Kürpig S, Rödel R, Essler M, Thomas L, Ahmadzadehfar H.
J Radiol Prot. 2019 Jun;39(2):387-398. doi: 10.1088/1361-6498/ab044d. Epub 2019 Feb 4.
PMID: 30716726
19. 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, von Mallek D, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1054-1062. doi: 10.1007/s00259-019-4258-6. Epub 2019 Jan 29.
PMID: 30697649
20. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H.
Endocr Relat Cancer. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424.
PMID: 30540557
21. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.
Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, Gaertner FC, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24.
PMID: 30474706
22. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A.
PET Clin. 2018 Oct;13(4):491-503. doi: 10.1016/j.cpet.2018.05.005. Epub 2018 Aug 17.
PMID: 30219184 Review.
23. [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.
Rahbar K, Ahmadzadehfar H, Seifert R, Boegemann M.
Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8.
PMID: 30102221 No abstract available.
24. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Fimmers R, Essler M, Ahmadzadehfar H.
Clin Cancer Res. 2018 Oct 1;24(19):4672-4679. doi: 10.1158/1078-0432.CCR-18-0947. Epub 2018 Jun 27.
PMID: 29950352
25. PSMA Theranostics: Current Status and Future Directions.
Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H.
Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068.
PMID: 29873291 Free PMC article. Review.
26. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
Awang ZH, Essler M, Ahmadzadehfar H.
Radiat Oncol. 2018 May 23;13(1):98. doi: 10.1186/s13014-018-1037-7.
PMID: 29792198 Free PMC article. Review.
27. BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
Ahmadzadehfar H, Gaertner F, Lossin PS, Schwarz B, Essler M.
Clin Nucl Med. 2018 Aug;43(8):609-610. doi: 10.1097/RLU.0000000000002141.
PMID: 29762244
28. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M.
Urologe A. 2018 Jun;57(6):709-713. doi: 10.1007/s00120-018-0642-2.
PMID: 29671080 German.
29. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy.
Ahmadzadehfar H, Essler M.
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
PMID: 29653975 No abstract available.
30. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G.
Breast Cancer Res Treat. 2018 Jun;169(3):447-455. doi: 10.1007/s10549-018-4717-y. Epub 2018 Feb 17.
PMID: 29455299
31. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.
Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M.
Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28.
PMID: 29262549 Free PMC article.
32. 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
Rahbar K, Ahmadzadehfar H, Boegemann M.
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):513-514. doi: 10.1007/s00259-017-3892-0. Epub 2017 Nov 21.
PMID: 29164300 No abstract available.
33. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246. doi: 10.1007/s00259-017-3877-z. Epub 2017 Nov 13.
PMID: 29134280
34. Theranostics in nuclear medicine practice.
Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, Essler M.
Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671. eCollection 2017.
PMID: 29042793 Free PMC article. Review.
35. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19. doi: 10.1007/s00259-017-3848-4. Epub 2017 Oct 12.
PMID: 29026946
36. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.
Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M.
Oncotarget. 2017 Jul 6;8(33):55094-55103. doi: 10.18632/oncotarget.19049. eCollection 2017 Aug 15.
PMID: 28903405 Free PMC article.
37. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.
Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M.
Oncotarget. 2017 Feb 25;8(33):55567-55574. doi: 10.18632/oncotarget.15698. eCollection 2017 Aug 15.
PMID: 28903443 Free PMC article.
38. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46. doi: 10.1007/s00259-017-3816-z. Epub 2017 Sep 1.
PMID: 28864881
39. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763.
PMID: 28719450
40. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. doi: 10.1007/s00259-017-3716-2. Epub 2017 May 9.
PMID: 28488028
41. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.
Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479. doi: 10.1007/s00259-017-3681-9. Epub 2017 Mar 23.
PMID: 28337529
42. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.
Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214. doi: 10.1007/s00259-017-3652-1. Epub 2017 Mar 1.
PMID: 28246882
43. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.
Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M.
Horm Metab Res. 2017 Feb;49(2):77-85. doi: 10.1055/s-0042-121894. Epub 2017 Jan 18.
PMID: 28099977 Review.
44. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ.
J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.
PMID: 27765862
45. Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis.
Yordanova A, Mayer K, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Dec;41(12):977-979. doi: 10.1097/RLU.0000000000001386.
PMID: 27749410
46. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Wei X, Schlenkhoff C, Sopora C, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Nov;41(11):894-895. doi: 10.1097/RLU.0000000000001358.
PMID: 27607162
47. 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.
Rahbar K, Bögemann M, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):166-167. doi: 10.1007/s00259-016-3530-2. Epub 2016 Oct 4.
PMID: 27699719 No abstract available.
48. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.
Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, Kürpig S, Strunk H, Essler M.
J Nucl Med. 2017 Mar;58(3):438-444. doi: 10.2967/jnumed.116.178533. Epub 2016 Sep 22.
PMID: 27660148
49. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H.
J Nucl Med. 2017 Feb;58(2):312-319. doi: 10.2967/jnumed.116.178228. Epub 2016 Sep 1.
PMID: 27587707
50. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H.
J Nucl Med. 2016 Sep;57(9):1334-8. doi: 10.2967/jnumed.116.173757. Epub 2016 Apr 7.
PMID: 27056618
51. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Schlenkhoff CD, Knüpfer E, Essler M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Jul;41(7):572-3. doi: 10.1097/RLU.0000000000001200.
PMID: 26909718
52. Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H.
Clin Nucl Med. 2016 Jun;41(6):478-80. doi: 10.1097/RLU.0000000000001195.
PMID: 26909716
53. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M.
Oncotarget. 2016 Mar 15;7(11):12477-88. doi: 10.18632/oncotarget.7245.
PMID: 26871285 Free PMC article.
54. 68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.
Schlenkhoff CD, Gaertner F, Essler M, Hauser S, Ahmadzadehfar H.
Clin Nucl Med. 2016 May;41(5):423-5. doi: 10.1097/RLU.0000000000001158.
PMID: 26859213
55. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M, Essler M.
EJNMMI Res. 2015 Dec;5(1):114. doi: 10.1186/s13550-015-0114-2. Epub 2015 Jun 20.
PMID: 26099227 Free PMC article.
56. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, Biersack HJ, Guhlke S, Reichmann K.
Clin Nucl Med. 2012 Jun;37(6):e141-7. doi: 10.1097/RLU.0b013e31823926e5.
PMID: 22614212
57. Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy.
Sabet A, Ezziddin S, Heinemann F, Guhlke S, Muckle M, Willinek W, Biersack HJ, Ahmadzadehfar H.
Nuklearmedizin. 2012;51(3):95-100. doi: 10.3413/Nukmed-0428-11-08. Epub 2012 Mar 16.
PMID: 22421930
58. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.
Ezziddin S, Lauschke H, Schaefers M, Meyer C, van Essen M, Biersack HJ, Kwekkeboom DJ, Ahmadzadehfar H.
Clin Nucl Med. 2012 Jan;37(1):102-4. doi: 10.1097/RLU.0b013e318238f111.
PMID: 22157044 No abstract available.
59. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy.
Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, Brockmann H, Willinek W, Wardelmann E, Biersack HJ, Ahmadzadehfar H.
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):459-66. doi: 10.1007/s00259-010-1610-2. Epub 2010 Sep 18.
PMID: 20852858
© 2024 Klinikum Westfalen GmbH